Eli Lilly has emerged as a popular growth stock thanks to its strength in the weight loss space. But the pharma giant also has an enormous opportunity in the Alzheimer's Disease market. Yet ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

It is tailored to patients being treated with Lilly's oncology drugs – which ... according to World Health Organization (WHO) figures, accounting for 11% of all forms of cancer.

At close: March 27 at 5:35:41 PM GMT+1 ...

While tariffs have triggered market volatility, certain pharmaceutical stocks still present strong investment opportunities.

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

VIG's recent rebalancing impacts its holdings, yield, and dividend growth streak. Read here for a comparison with SPY, DGRO, ...

Through Synapticure, patients will be able to use LillyDirect to find in-person Alzheimer’s specialists or to connect with ...